IB DCE

Imaging Biometrics

IB DCE calculates parameters for solid tumor perfusion and permeability analysis. IB DCE includes the Tofts, Extended Tofts, and Patlak models. IB DCE can be used to monitor tumor response to antiangiogenic and vascular disrupting agents, radiotherapy, and chemotherapy.

Information source: Vendor
Last updated: July 31, 2020

General Information

General
Product name	IB DCE
Company	Imaging Biometrics
Subspeciality	Multiple
Modality	MR
Disease targeted	Tumors
Key-features	Automated generation of perfusion parameter maps and Vascular Input Function, anatomical image registration, report generation
Suggested use

Technical Specifications

Data characteristics
Population
Input	Dynamically acquired DCE datasets
Input format	DICOM
Output	Quantitative output of multi-parameter DCE maps
Output format	DICOM
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Hybrid solution
Trigger for analysis	Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	10 - 60 seconds

Regulatory

Certification
CE	Certified, Class I , MDD
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)

Market

Market presence
On market since	01-2013
Distribution channels	Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, aycan Medical Systems, Pixmeo, Calantic
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use, Subscription
Based on	Number of users, Number of installations, Number of analyses

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers